Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors

NCT05759949 is registered in ClinicalTrials.gov with Relay Therapeutics, Inc. as lead sponsor.

NCT NCT05759949
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05759949 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of PI3Kα Inhibitor, RLY-5836, in Combination With Targeted and Endocrine Therapies in Participants With Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors
Lead sponsor
Relay Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 29, 2023
Completion date
April 11, 2025
Enrollment
41 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, her2-negative breast cancer, hormone receptor positive tumor, metastatic breast cancer, pik3ca mutation, solid tumor, adult, unresectable solid tumor